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Summary
Protein tyrosine phosphatase 1B (PTP1B) is a highly
specific negative regulator of insulin receptor signal-
ing in vivo. The determinants of PTP1B specificity for
the insulin receptor versus other receptor tyrosine
kinases are largely unknown. Here, we report a crystal
structure at 2.3 A˚ resolution of the catalytic domain of
PTP1B (trapping mutant) in complex with the phos-
phorylated tyrosine kinase domain of the insulin
receptor (IRK). The crystallographic asymmetric unit
contains two PTP1B-IRK complexes that interact
through an IRK dimer interface. Rather than binding
to a phosphotyrosine in the IRK activation loop,
PTP1B binds instead to the opposite side of the kinase
domain, with the phosphorylated activation loops se-
questered within the IRK dimer. The crystal structure
provides evidence for a noncatalytic mode of interac-
tion between PTP1B and IRK, which could be impor-
tant for the selective recruitment of PTP1B to the insu-
lin receptor.
Introduction
Insulin activates intracellular signaling pathways that
regulate cellular metabolism and growth (Saltiel and
Pessin, 2002). The actions of insulin are mediated by
its transmembrane receptor, an a2b2 glycoprotein and
member of the receptor tyrosine kinase (RTK) family of
cell surface receptors (Ebina et al., 1985; Ullrich et al.,
1985). Insulin binding to the extracellular a chains in-
duces a structural change within the receptor, facilitat-
ing autophosphorylation of specific tyrosine residues in
the cytoplasmic portion of the b chains. Tyrosine phos-
phorylation increases the catalytic activity of the recep-
tor and also generates recruitment sites for downstream
signaling proteins, such as the insulin receptor sub-
strate (IRS) proteins (White, 1998), Shc (Gustafson
et al., 1995), APS (Ahmed et al., 1999; Moodie et al.,
1999), and SH2-B (Kotani et al., 1998).
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including both receptor and nonreceptor types, serves
to attenuate activated RTK signaling pathways, or to
maintain basal-level phosphorylation levels, by dephos-
phorylating RTKs as well as their substrate proteins
(Tonks and Neel, 1996). In cell culture experiments, sev-
eral PTPs, including LAR, PTPa, and PTP1B have been
shown to be capable of dephosphorylating the insulin
receptor (Asante-Appiah and Kennedy, 2003). An impor-
tant advance in our understanding of insulin receptor
downregulation in vivo came from the generation of
PTP1B-deficient mice (Elchebly et al., 1999; Klaman
et al., 2000). Despite the ability of PTP1B to dephosphor-
ylate numerous growth factor receptors in vitro and in
cells, the PTP1B-deficient mice are of normal size (i.e.,
no overgrowth phenotype) and exhibit only two appar-
ent phenotypes: a hypersensitivity to insulin, due to pro-
longed insulin receptor phosphorylation, and resistance
to weight gain on a high-fat diet, through sustained ac-
tivity of Jak2 associated with the leptin receptor (Myers
et al., 2001; Zabolotny et al., 2002). The mice knockout
studies established that PTP1B has highly specific tar-
gets in vivo, one of which is the insulin receptor.
PTP1B is a cytoplasmic, nonreceptor PTP that is teth-
ered to the endoplasmic reticulum (ER) by a hydrophobic
sequence at its C terminus (Tonks, 2003). While many
nonreceptor PTPs are targeted to their substrates via
recognizable protein interaction modules, such as the
Src homology-2 (SH2) domains in SHP2, PTP1B has
few obvious recruitment domains/motifs, except for a
proline-rich region C-terminal to the catalytic domain,
which binds SH3 domain-containing proteins such as
p130Cas (Liu et al., 1996). PTP1B is ubiquitously ex-
pressed in vertebrates, and many RTKs undergo ligand-
stimulated endocytosis, which would bring receptors
in proximity to the ER. Therefore, PTP1B specificity for
the insulin receptor does not derive from tissue-specific
coexpression or from a unique subcellular colocaliza-
tion. Rather, specificity likely arises from intrinsic sub-
strate (catalytic) preferences, i.e., the sequence context
of phosphorylation sites in the insulin receptor, and/or
targeting of PTP1B to the insulin receptor through non-
catalytic protein-protein interactions.
Previous crystallographic and biochemical studies
of the interaction between a PTP1B trapping mutant
(which binds to but does not hydrolyze phosphotyro-
sine) and a phosphopeptide representing the activation
loop of the insulin receptor kinase domain (IRK) indi-
cated that the tandem phosphotyrosine residues
pY1162 and pY1163 in the kinase activation loop are im-
portant determinants of specificity, and that the N- and
C-terminal flanking residues, aspartic acid and arginine,
might also contribute (Salmeen et al., 2000). Because
numerous RTKs, particularly the highly related insulin-
like growth factor-1 (IGF1) receptor, fibroblast growth
factor receptor-1-4, TrkA/B/C, and MuSK, possess tan-
dem activation loop tyrosines in a similar sequence con-
text, (D/E)YY(R/K), it is unlikely that this sequence motif
is sufficient to account for the observed in vivo specific-
ity of PTP1B for the insulin receptor.
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lin-stimulated PTP1B tyrosine phosphorylation had
shown that mutation of two tyrosine residues in the cat-
alytic domain of PTP1B, Y152 and Y153, reduced the in-
teraction between a PTP1B trapping mutant and the
insulin receptor (Bandyopadhyay et al., 1997). Subse-
quent studies demonstrated that the PTP1B Y152F/
Y153F double mutant was much less efficient at de-
phosphorylating the insulin receptor than wild-type
PTP1B, yet these phenylalanine substitutions had no ef-
fect on PTP1B dephosphorylation of a control phospho-
peptide or of p130Cas (Dadke et al., 2000; Dadke and
Chernoff, 2002). These studies provided evidence for in-
teractions between PTP1B and the insulin receptor that
are distal to the PTP1B active site.
In an effort to elucidate further the molecular determi-
nants of PTP1B specificity for the insulin receptor, we
have cocrystallized a trapping mutant of PTP1B with
phosphorylated IRK. The crystal structure of the com-
plex shows an unanticipated mode of interaction be-
tween PTP1B and IRK, in which PTP1B binds not to
a phosphotyrosine in the IRK activation loop, but rather
to the opposite side of the kinase domain. The PTP1B-
IRK interface comprises residues that are highly charac-
teristic for these two proteins, including Y152 and Y153
of PTP1B. The PTP1B-IRK crystal structure indicates
that a noncatalytic mode of interaction between PTP1B
and the insulin receptor could play an important role in
the in vivo specificity of PTP1B for the insulin receptor.
Results
Overall Structure of the PTP1B-IRK Complex
For cocrystallization trials, we used a C215A trapping
mutant of PTP1B (residues 1–298) and tris-phosphory-
lated IRK (residues 978–1283) in which Y1158, Y1162,
and Y1163 in the activation loop were phosphorylated.
Orthorhombic crystals were obtained at pH 7.5 in am-
monium sulfate. The crystal structure of the complex
was solved by molecular replacement by using the indi-
vidual structures of PTP1B (Salmeen et al., 2000) and
tris-phosphorylated IRK (Hubbard, 1997) as search
models. The structure has been refined at 2.3 A˚ resolu-
tion with an Rcryst value of 21% (Rfree value of 24%).
Data collection and refinement statistics are given in
Table 1. The crystallographic asymmetric unit com-
prises two molecules each of PTP1B and IRK, arranged
as a symmetric dimer of two 1:1 PTP1B-IRK complexes
that interact through an IRK dimer interface (Figure 1).
In the previous crystal structure of PTP1B in complex
with a phosphopeptide representing the IRK activation
loop (Salmeen et al., 2000), pY1162 is bound in the active
site of the PTP1B trapping mutant, poised for dephos-
phorylation. This structure is indicative of a catalytic
mode of interaction between PTP1B and its substrate
phosphopeptide. The striking feature of the present
PTP1B-IRK structure is the binding of PTP1B to the
‘‘backside’’ of the kinase domain rather than to a phos-
photyrosine in the activation loop (‘‘front’’ side). This
mode of binding between PTP1B and IRK is evidently fa-
cilitated by crystallization in ammonium sulfate, which
effectively competes with the activation loop phospho-
tyrosines for PTP1B binding; a well-ordered sulfate ion is
bound in the PTP1B active site. Thus, the present struc-ture represents a noncatalytic mode of interaction be-
tween PTP1B and IRK.
PTP1B-IRK Interface
The interface between PTP1B and IRK, which is nearly
identical in the two copies of PTP1B-IRK present in the
asymmetric unit, buries a total surface area of w1725
A˚2, with a shape complementarity value of 0.70 (Law-
rence and Colman, 1993). These values are on par with
biologically relevant protein-protein interactions, such
as antibody-antigen complexes (Janin and Chothia,
1990). There are two main PTP1B-IRK interaction re-
gions that encompass both the N- and C-terminal lobes
of IRK: the b2-b3 loop of IRK (N-terminal lobe) with the
b9-b10 turn of PTP1B, and a helix J (aJ) of IRK (C-termi-
nal lobe) with the WPD loop (between b11 and a2) of
PTP1B (Figure 1).
The key interaction between the N-terminal lobe of
IRK and PTP1B is the hydrogen bond between E1022
(denoted E1022I) in the b2-b3 loop of IRK and Y152 (de-
noted Y152P) in the b9-b10 turn of PTP1B (Figure 2B).
N193P (a3) also contacts the b2-b3 loop of IRK, making
a hydrogen bond with the backbone of G1021I and a
water-mediated hydrogen bond with the backbone of
A1023I. Y153P (b10) is in van der Waals contact with
the backbone of G1021I. Two intramolecular interac-
tions favorably position Y152P and E1022I for hydrogen
bonding with each other: N193P is hydrogen bonded to
Y152P, and T1025I (b3) is hydrogen bonded to E1022I
(Figure 2B).
The WPD loop of PTP1B (residues 179–184), which
contains the PTP-conserved catalytic residue D181,
Table 1. X-Ray Data Collection and Refinement Statistics
Data Collection
Resolution (A˚) 30.0–2.3
Observations 208,286
Unique reflections 60,480
Completenessa (%) 98.1 (94.2)
Rsym
a,b (%) 10.4 (27.2)
<I/sI> 8.0
Refinementc
Resolution (A˚) 30.0–2.3
Reflections 58,237
Rcryst/Rfree
d (%) 20.8/23.9
Rms deviations
Bond lengths (A˚) 0.006
Bond angles (º) 1.3
B factorse (A˚2) 1.1
Average B factors (A˚2)
All atoms 23.4
PTP1B 21.8
IRK 24.8
Water 24.5
Sulfate 36.2
a The overall (30–2.3 A˚) value is given first, with the value in the high-
est resolution shell (2.38–2.30 A˚) given in parenthesis.
b Rsym = 100 3 SjI 2 <I>j/SI.
c Atomic model includes 1161 residues (9216 atoms), 10 sulfate ions
(50 atoms), and 377 water molecules (377 atoms).
d Rcryst = 1003 SkFoj2 jFck/SjFoj, where Fo and Fc are the observed
and calculated structure factors, respectively (Fo > 0s). Rfree was
determined from 5% of the data.
e For bonded protein atoms.
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1645Figure 1. Ribbon Diagram of the PTP1B-IRK
Crystal Structure
The two PTP1B molecules are colored cyan,
and the two IRK molecules are colored yellow
and green. The catalytic loops of PTP1B (res-
idues 215–218) and IRK (residues 1130–1137)
are colored red, and the WPD loop of PTP1B
(residues 179–184) and the activation loop of
IRK (residues 1150–1171) are colored gray.
The activation loop phosphotyrosines of IRK
are shown in ball-and-stick representation,
with carbon atoms colored yellow or green,
oxygen atoms colored red, and phosphorus
atoms colored black. Select secondary struc-
ture elements are indicated in one of the two
1:1 PTP1B-IRK complexes in the top panel.
The N termini of the IRK molecules, which
would lead into the juxtamembrane region
and transmembrane helix of the insulin re-
ceptor, are labeled ‘‘N.’’ In the top panel, the
noncrystallographic 2-fold axis is perpendic-
ular to the page, and in the bottom panel, the
2-fold axis is vertical, in the plane of the page.
Figures 1–4 were rendered with Pymol soft-
ware (www.pymol.org).makes several contacts with residues in and preceding
aJ of IRK (Figure 2C), a helix that is unique to the insulin
receptor subfamily of RTKs. Hydrophobic packing inter-
actions in this interface include P180P (WPD loop) with
V1274I (aJ) and F182P (WPD loop) with P1269I. Addi-
tional interactions in this region include a salt bridge be-
tween K120P (b6-b7 loop) and E1273I (aJ), a hydrogen
bond between R112P (b4-b5 loop) and the backbone of
E1273I, and a hydrogen bond between H1268I (aI-aJ
loop) and the backbone of F182P. These interactions be-
tween aJ of IRK and the WPD loop promote a closed
conformation of this catalytically important loop, which
typically adopts an open conformation in the absence
of a phosphotyrosine in the catalytic site.
Additional interactions in the PTP1B-IRK interface in-
clude the b7-b8 loop of IRK (C-terminal lobe) with the
b11-a2 loop of PTP1B (Figure 2C) and the kinase insert
region of IRK (aD-aE loop) with a10 of PTP1B (Figure 1).
A full listing of the interactions in the PTP1B-IRK inter-
face is given in Table 2.
Comparison of the PTP1B Structure
with Previous Structures
A superposition of the PTP1B structure from the PTP1B-
IRK complex with the PTP1B structure with the bound
IRK activation loop phosphopeptide (Salmeen et al.,2000) (PDB code 1G1F) reveals a very similar overall
conformation, with a root mean square deviation of 0.6
A˚ for 270 Ca atoms, but with several notable differences
(Figure 3). The most conspicuous difference is the be-
havior of the C-terminal segment of PTP1B, residues
283–298. In previous crystal structures of PTP1B with
a phosphotyrosine ligand bound in the active site (e.g.,
PDB code 1G1F), the WPD loop adopts a closed confor-
mation, and residues in the C-terminal segment form an
a helix (a7), which interacts with a3 and the b9-b10 turn.
Conversely, in structures of apo PTP1B or PTP1B with
an ion bound in the active site (e.g., PDB code 2HNQ
[Barford et al., 1994]), the WPD loop adopts an open
conformation, and the C-terminal segment is disor-
dered. In the PTP1B-IRK structure, despite the WPD
loop adopting a closed conformation, residues 283–
298 are disordered. The interaction between the b2-b3
loop of IRK and the b9-b10 turn of PTP1B evidently dis-
places a7 of PTP1B (Figure 3), causing its disordering.
Interestingly, a recently described allosteric inhibitor of
PTP1B also displaces a7, which impairs closure of the
WPD loop (Wiesmann et al., 2004).
Another difference in the PTP1B structure as com-
pared to previous structures is the b5/b6 region (resi-
dues 111–120) (Figure 3B). Residues 115–117 are disor-
dered in the PTP1B-IRK complex, and residues 112–114
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Interface
(A) Overall view of the PTP1B-IRK interface
with PTP1B and IRK shown in ribbon repre-
sentation with semitransparent molecular
surfaces. PTP1B is colored cyan, and IRK is
colored yellow. The orientation is approxi-
mately half way between the upper and lower
panels of Figure 1. The black rectangles indi-
cate the zoom areas in (B) and (C). The cata-
lytic loops of PTP1B and IRK are colored
red, and the WPD and activation loops are
colored gray.
(B) Stereoview of the interactions between
the b2-b3 loop of IRK and the b9-b10 turn
and a3 of PTP1B. Carbon atoms are colored
cyan (PTP1B) or yellow (IRK), oxygen atoms
are colored red, and nitrogen atoms are col-
ored blue. Hydrogen bonds are represented
by dashed lines.
(C) Stereoview of the interactions between aJ
of IRK and the WPD loop of PTP1B. The col-
oring is the same as in (B).and 118–119 adopt a different conformation than previ-
ously observed. This difference is likely due to the inter-
action of IRK with PTP1B residues in this region, namely,
R112P and K120P (Figure 2C).
In most previous PTP1B structures, E115P (b5) is salt
bridged to PTP-conserved R221P (a4). In the PTP1B-
IRK structure, R221P is salt bridged to a sulfate ion
rather than to E115P. The lack of an E115-R221 salt
bridge was also observed in the structure of the SHP1
phosphatase domain with bound phosphopeptide
(Yang et al., 2000). In this case, residues of the peptide
that are C-terminal to phosphotyrosine interact withthe b5/b6 region of PTP1B, altering its conformation.
Of note, in the PTP1B-IRK structure, the b5/b6 region
is not sterically precluded by IRK from adopting the con-
ventional conformation with an intact R221-E115 salt
bridge.
Three well-ordered sulfate ions are bound to each
PTP1B molecule (Figure 3B). One sulfate ion is located
in the PTP1B active site, in the position of a substrate
phosphate group. Another sulfate ion is located in the
noncatalytic aryl pocket previously identified as a sec-
ond phosphotyrosine binding site (Puius et al., 1997;
Salmeen et al., 2000). The third sulfate ion is bound to
Crystal Structure of a PTP1B-IRK Complex
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N111P and K120P.
IRK-IRK Interface
The two PTP1B-IRK complexes in the asymmetric unit,
related by a noncrystallographic 2-fold axis, interact
through a kinase interface comprising N-terminal lobe
regions aC, the b3-aC loop, and the b4-b5 loop (Figure
4). The total surface area buried in this interface is
1575 A˚2, with a shape complementarity value of 0.64.
The main contact element is aC, in which four hydropho-
bic residues, L1038, I1042, L1045, and A1048, interdigi-
tate in antiparallel fashion with the corresponding res-
idues from the other kinase molecule (Figure 4B).
Hydrophobicity at all four positions is conserved in the
insulin receptor subfamily (e.g., the IGF1 receptor), but
not in other RTK subfamilies.
In addition to these interactions, several hydrogen
bonds fortify the interface. R1041 in aC is hydrogen
bonded to the backbone of the b4-b5 loop of the IRK di-
mer partner, and a backbone-backbone hydrogen bond
is made between the b4-b5 loop of one IRK molecule
and the b3-aC loop of the other molecule (Figure 4B).
The side chain of Q1070 in the b4-b5 loop makes
a long hydrogen bond (3.4 A˚) with R1041 of the other
IRK protomer. In this IRK dimer configuration, the acti-
vation loop phosphotyrosines are clustered inside the
dimer, and the kinase active sites face outward and
are unobstructed (Figure 1).
Comparison of the IRK Structure with Previous
Structures
The structure of tris-phosphorylated IRK in the PTP1B-
IRK complex is similar to the ternary structure of tris-
Table 2. Interactions in the PTP1B-IRK Interface
PTP1B Residue Interactions with IRK
R112 (b4-b5 loop) H bonded to E1273 backbone
K120 (b6-b7 loop) Salt bridged to E1273 side chain
K150 (b9) van der Waals contact with G1021
Y152 (b9-b10 turn) H bonded to E1022 side chain
Y153 (b10) van der Waals contact with G1021 backbone
P180 (WPD loop) van der Waals contact with V1274 side chain
D181 (WPD loop) van der Waals contact with E1273 side chain
F182 (WPD loop) van der Waals contact with P1269 side chain
V184 (b11-a3 loop) van der Waals contact with D1143 side chain
N193 (a3) H bonded to G1021 backbone and A1023
backbone (water mediated)
R268 (a6) H bonded to H1142 backbone
IRK Residue Interactions with PTP1B
G1021 (b2-b3 loop) van der Waals contact with K150 and Y153
side chains
E1022 (b2-b3 loop) H bonded to Y152 side chain
P1102 (kinase insert) van der Waals contact with D11 and K12
backbone
H1142 (b7-b8 loop) H bonded to P185 backbone
D1143 (b7-b8 loop) van der Waals contact with V184 side chain
H1268 (aI-aJ loop) H bonded to F182 backbone
P1269 (aI-aJ loop) van der Waals contact with F182 side chain
E1273 (aJ) Salt bridged to K120 and van der Waals
contact with D181 side chain
V1274 (aJ) van der Waals contact with P180 side chain
Residues whose side chains are involved in interface contacts are
listed on the left side. Cut-off distances are 3.2 A˚ for hydrogen bonds
(H bonds) and 3.8 A˚ for van der Waals contacts.phosphorylated IRK in complex with an ATP analog
and peptide substrate (Hubbard, 1997), differing in two
significant aspects: lobe closure and oligomeric state.
With respect to IRK in the ternary structure, the N-terminal
lobe of IRK is rotated toward the C-terminal lobe byw9º
in the PTP1B-IRK complex, i.e., the IRK structure in the
complex is slightly more closed. This is evidently due to
the imposition of the b9-b10 turn of PTP1B on the b2-b3
loop of IRK (Figures 2A and 2B). Because backside bind-
ing of PTP1B to IRK involves simultaneous engagement
of both kinase lobes, this binding mode will be sensitive
to the relative disposition of the two lobes. This could
explain the observation that, in solution, PTP1B does
not bind appreciably to unphosphorylated IRK (data
not shown), in which the lobes are stabilized in an
open state (Hubbard et al., 1994).
Previous crystal structures of IRK—wild-type, mutant,
unphosphorylated, and phosphorylated—have all been
of a monomeric kinase domain. In the PTP1B-IRK
structure, a dimeric configuration of IRK is observed.
Whether the two kinase domains in the holoreceptor
stably interact as a dimer, either before or after insulin-
triggered autophosphorylation, is not known. Upon au-
tophosphorylation, the kinase-proximal juxtamembrane
region of the insulin receptor disengages from a cleft be-
tween aC and the b sheet in the N-terminal kinase lobe,
which exposes aC residues I1042, L1045, and A1048 (Li
et al., 2003). These residues, along with L1038, form the
IRK dimer interface (Figure 4B), suggesting the possibil-
ity that the dimeric state of IRK as observed in the
PTP1B-IRK crystal structure could reflect the arrange-
ment of the two activated kinase domains in the intact
receptor.
Discussion
Specificity in the PTP1B-IRK Interface
The crystal structure of the PTP1B-IRK complex pre-
sented here reveals a noncatalytic mode of interaction
between PTP1B and phosphorylated IRK, which is
highly specific for these two proteins. From sequence
alignments and the known structures of kinase domains
of RTKs, only the insulin receptor subfamily contains the
short a helix J at the end of the kinase domain, which re-
directs the polypeptide chain toward the backside of the
kinase. Several residues in and preceding this helix in
IRK contact the WPD loop of PTP1B (Figure 2C). Fur-
thermore, a sequence alignment of insulin receptor sub-
family members reveals that the IRK residues in the
PTP1B-IRK interface are unique to the insulin receptor.
Even the highly related IGF1 receptor, with 81% se-
quence identity in the tyrosine kinase domain, would
not be predicted to engage PTP1B on the backside of
the kinase domain because of substitutions at PTP1B-
IRK interface residues G1021 (to D; b2-b3 loop), H1142
(to E; b7-b8 loop) and H1268 (to E; aI-aJ loop).
A sequence alignment of PTPs (Andersen et al., 2001)
also highlights the specific nature of the PTP1B-IRK in-
terface. Y152 (b9-b10 turn) and N193 (a3), which are hy-
drogen bonded to the b2-b3 loop of IRK (Figure 2B), are
highly variable in the PTP family. In SHP2, for example,
aspartic acid residues are found at the equivalent posi-
tions of Y152 and N193, which would be disfavored for
IRK binding. In the WPD loop of PTP1B, F182 is in van
Structure
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(A) The Ca trace of PTP1B from the PTP1B-
IRK complex is colored cyan, and the super-
imposed Ca trace from the PTP1B-phospho-
peptide structure (Salmeen et al., 2000) (PDB
code 1G1F) is colored orange. The WPD loop
(residues 179–184) in each PTP1B structure is
colored gray, and the catalytic loop (residues
215–218) is colored red. The b2-b3 loop of IRK
from the PTP1B-IRK structure is colored yel-
low, and the IRK phosphopeptide from the
1G1F structure is colored magenta. Select
secondary structure elements are labeled,
and the N and C termini of the two PTP1B
structures are denoted by ‘‘N’’ and ‘‘C,’’ re-
spectively. The first ordered residue in both
structures is E2, while the last ordered residue
is M282 in the PTP1B-IRK structure and D298
in the 1G1F structure. Where termini or sec-
ondary structure elements overlap between
the two PTP1B structures, the labels are col-
ored black, otherwise they are colored cyan
(PTP1B-IRK) or orange (1G1F). The black
rectangle indicates the zoom area in (B).
(B) Stereoview near the active site of PTP1B.
Select side chains of the two PTP1B struc-
tures, as well as the sulfate ions (labeled S1,
S2, and S3) in the PTP1B-IRK structure, are
shown in ball-and-stick representation. Car-
bon atoms are colored cyan (PTP1B from
PTP1B-IRK), orange (PTP1B from 1G1F), or
magenta (phosphopeptide from 1G1F), oxy-
gen atoms are colored red, nitrogen atoms
are colored blue, phosphorus atoms are col-
ored black, and sulfur atoms are colored
green.der Waals contact with P1269 (aI-aJ loop) of IRK (Figure
2C). In PTPs, this residue is most often a histidine.
TCPTP, which shares 70% sequence identity with
PTP1B (residues 1–298), is the only other PTP that pos-
sesses the same key PTP1B-IRK interface residues
(Y152, N193, P180, and F182). Recent biochemical stud-
ies with TCPTP-deficient cells have implicated TCPTP
as well as PTP1B in the coordinated downregulation of
insulin receptor signaling (Galic et al., 2005).
Possible Role for Backside Binding
The PTP1B-IRK crystal structure provides a plausible
structural basis for the previously reported observations
that Y152 and Y153 of PTP1B are determinants in the in-
teraction of PTP1B with the insulin receptor (Bandyo-
padhyay et al., 1997; Dadke et al., 2000; Dadke and
Chernoff, 2002). In the crystal structure, Y152 and
Y153 interact with the b2-b3 loop of IRK (Figure 2B). In-
terestingly, insulin-stimulated phosphorylation of Y152
and Y153, for which there is biochemical evidence (Ban-
dyopadhyay et al., 1997), would be predicted to abro-
gate backside binding of PTP1B to the insulin receptor.
In light of the biochemical data supporting a role for
PTP1B residues Y152 and Y153 in the interaction withthe insulin receptor, it is unlikely that the PTP1B-IRK in-
teraction observed in the crystal structure is an artifact
resulting from crystallization in ammonium sulfate (one
of the most common protein crystallization agents).
The significant buried surface area (1725 A˚2) and favor-
able shape complementarity (0.70), as well as two crys-
tallographically independent copies of the PTP1B-IRK
complex in the asymmetric unit, also argue for the phys-
iologic relevance of the PTP1B-IRK interface. It appears
that ammonium sulfate in the crystallization medium
acted (serendipitously) to suppress the catalytic, phos-
photyrosine-dependent interaction between PTP1B
and IRK, revealing a noncatalytic mode of binding,
which could be important for the selective recruitment
of PTP1B to the insulin receptor.
PTP1B encounters the insulin receptor both as a
single-chain receptor precursor in the ER and as a ma-
ture a2b2 heterotetramer upon insulin-stimulated recep-
tor endocytosis. It has been known for some time that
the insulin receptor precursor is particularly sensitive
to dephosphorylation by PTP1B, because of tethering
of PTP1B to the ER (Lammers et al., 1993, 1997). Unlike
most other RTKs, the insulin receptor precursor must
undergo homodimerization in the ER in the course of
Crystal Structure of a PTP1B-IRK Complex
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Interface
(A) Overall view of the IRK dimer interface
with each IRK protomer shown in ribbon rep-
resentation with a semitransparent molecular
surface. The two protomers are colored yel-
low and green. The orientation is the same
as in the top panel of Figure 1. The black rect-
angle indicates the zoom area in (B).
(B) Stereoview of the interactions in the IRK
dimer interface. Carbon atoms are colored
yellow or green, oxygen atoms are colored
red, and nitrogen atoms are colored blue. Hy-
drogen bonds are represented by dashed
lines. The noncrystallographic 2-fold axis is
perpendicular to the page, in the center of
the diagram.receptor maturation (intermolecular disulfide formation).
Because of this requisite dimerization step, the potential
exists for insulin-independent signaling by an activated
(trans-phosphorylated) insulin receptor precursor.
Recent FRET (Romsicki et al., 2004) and BRET (Boute
et al., 2003; Issad et al., 2005) experiments examining
the interaction between PTP1B (trapping mutant) and
the insulin receptor in living cells have demonstrated
that there is a significant basal level of interaction be-
tween the two proteins, approximately half the insulin-
stimulated level, which is due to PTP1B interacting with
the insulin receptor precursor. Interestingly, addition of
a catalytic site PTP1B inhibitor to cells substantially
decreased the insulin-stimulated FRET signal between
PTP1B and the insulin receptor, but not the basal
FRET signal (Romsicki et al., 2004). This observation is
suggestive of a noncatalytic mode of interaction be-
tween PTP1B and the insulin receptor precursor, such
as that observed in the PTP1B-IRK crystal structure.
Although we were not able to detect binding of PTP1B
to unphosphorylated IRK in solution, it is still possible
that, in the context of an ER-tethered PTP1B and a trans-
membrane insulin receptor, appreciable backside bind-
ing of PTP1B to an unphosphorylated receptor might
occur (reduced dimensionality effect), either to a mature
heterotetramer in the plasma membrane or to a receptor
precursor in the ER. This interaction mode could coloc-
alize PTP1B to the insulin receptor for rapid dephos-phorylation upon insulin-stimulated or adventitious
receptor phosphorylation. Indeed, it is has been previ-
ously observed that the association between a PTP1B
trapping mutant and the insulin-stimulated insulin re-
ceptor is rapid (w5 min) compared to the association
of PTP1B with the PDGF (platelet-derived growth factor)
and EGF (epidermal growth factor) receptors (w30 min)
(Haj et al., 2002; Boute et al., 2003; Romsicki et al., 2004;
Shi et al., 2004).
Another possible scenario is that PTP1B binds to the
backside of a phosphorylated insulin receptor. Because
of the high affinity of a PTP1B trapping mutant for phos-
phorylated IRK (front side binding: Kd w100 nM, data
not shown), any appreciable backside binding of wild-
type PTP1B to a phosphorylated insulin receptor would
require that the phosphotyrosine residues are protected
from facile PTP1B dephosphorylation. Partial protection
from dephosphorylation by PTPs, mediated by receptor
dimerization, has been demonstrated for the PDGF re-
ceptor (Shimizu et al., 2001). The PTP1B-IRK structure
presented here, in which the activation loop phospho-
tyrosines are sequestered in the center of the kinase di-
mer (Figure 1, bottom), provides a possible structural
mechanism for phosphatase protection. Alternatively,
insulin-stimulated oxidation of the catalytic cysteine
(C215) in PTP1B (Meng et al., 2004) would disrupt the
catalytic, phosphotyrosine-dependent interaction with
the insulin receptor, and thus favor backside binding.
Structure
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ments in cells will be necessary to determine the precise
cellular context for backside binding and the functional
consequences thereof.
Experimental Procedures
Protein Expression and Purification
The catalytic domain of PTP1B (residues 1–298), containing the sub-
strate trapping mutation C215A, was purified from E. coli according
to a protocol modified slightly from that reported previously (Barford
et al., 1994). E. coli strain BL21(DE3) was transformed with the
pET19b-PTP1B vector. An overnight culture was diluted 1:10 in fresh
LB and grown at 37ºC. When OD600 reached 0.6, isopropylthiogalac-
topyranoside (IPTG) was added to a final concentration of 0.6 mM,
and induction took place for 3 hr at 37ºC. Cells were collected by
centrifugation at 5000 3 g for 15 min. The cell pellet was resus-
pended in lysis buffer (20 mM imidazole [pH 7.5], 10% glycerol,
1 mM EDTA, 0.5 mM EGTA, 0.5 mM PMSF, 0.5 mM benzamidine,
and 3 mM DTT) and passed through a French Press at 16,000 psi.
The lysate was clarified by centrifugation at 15,000 3 g for 40 min
and loaded onto a Source-Q column (Amersham Biosciences) equil-
ibrated in 20 mM imidazole (pH 7.5), 10% glycerol, 1 mM EDTA, 0.5
mM EGTA, 0.5 mM PMSF, 0.5 mM benzamidine, and 3 mM DTT.
PTP1B was eluted by using a linear gradient of NaCl. PTP1B frac-
tions were pooled and dialyzed against 25 mM sodium phosphate
(pH 6.0), 10% glycerol, 1 mM EDTA, 0.5 mM EGTA, 0.5 mM PMSF,
0.5 mM benzamidine, and 3 mM DTT. PTP1B was then loaded
onto a Source-S column (Amersham Biosciences) equilibrated in
the same buffer and eluted by using a linear gradient of NaCl. Frac-
tions containing PTP1B were pooled and exchanged into 20 mM
Tris-HCl (pH 7.5), 50 mM NaCl, and 5 mM DTT and were concen-
trated tow20 mg/ml in a Centricon-30 microconcentrator (Amicon).
Production of tris-phosphorylated IRK was as previously described
(Hubbard, 1997).
Crystallization, Data Collection, and Structure Determination
Purified PTP1B(C215A) and tris-phosphorylated IRK were mixed at
a 1:1 molar ratio, as monitored by native gel electrophoresis, at a final
protein concentration ofw5 mg/ml. Crystals of PTP1B and IRK were
obtained by the hanging drop vapor diffusion method at 4ºC. A total
of 1 or 2 ml stock protein complex was mixed with an equal volume of
reservoir buffer (100 mM Tris-HCl [pH 7.5], 1.9 M ammonium sulfate,
and 2% polyethylene glycol [PEG] 400) and was suspended over
500 ml reservoir buffer. Crystals appeared within several days and
grew to maximum size (150 3 150 3 20 mm) in approximately
2 weeks. The crystals belong to primitive orthorhombic space group
P212121 with unit cell dimensions of a = 87.47 A˚, b = 88.16 A˚, c =
178.04 A˚. There are two PTP1B and two IRK molecules per asym-
metric unit, giving a solvent content of 50%.
Crystals were cryoprotected in 1.9 M ammonium sulfate, 100 mM
Tris-HCl (pH 7.5), 9% sucrose, 2% glucose, 8% glycerol, and 8%
ethylene glycol and were flash frozen in liquid propane. Data were
collected from a single frozen crystal at beamline X25 at the National
Synchrotron Light Source, Brookhaven National laboratory. All data
were processed with DENZO and SCALEPACK (Otwinowski and Mi-
nor, 1997). The structure of the complex was determined by molec-
ular replacement with the program AMoRe (Navaza, 1994) with pre-
viously determined structures for tris-phosphorylated IRK (1IR3) and
PTP1B (1G1H) used as search models. Simulated-annealing, rigid-
body, positional, and B factor refinement were carried out by using
CNS (Bru¨nger et al., 1998). Model building was performed with O
(Jones et al., 1991). The atomic model for IRK includes residues
987–1283 in both copies in the asymmetric unit, and the atomic
model for PTP1B includes residues 2–292 for one molecule, except
for residues 115–116, and residues 2–282 for the other molecule, ex-
cept for residues 115–117.
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